Safety Analysis of Chronic Intake of a β-alanine Supplement (HIPOX-β)

Universidad Católica San Antonio de Murcia

Status

Completed

Conditions

Product Safety

Treatments

Other: Control product consumption

Dietary Supplement: Beta-alanine

Study type

Interventional

Funder types

Other

Identifiers

NCT05334121

UCAMCFE-00025

Details and patient eligibility

About

Single-center, double-blind, placebo-controlled clinical trial with two arms (product and placebo) to analyze the safety of beta-alanine consumption in active people.

Full description

After recruitment, subjects will be randomized and assigned to one of the two arms of the study: beta-alanine group or control group (placebo).

Subjects must be active people, and will take a dose of 15 g per day of the product for 4 weeks.

Enrollment

20 patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men between 18 and 40 years of age.
Physically active people. They must train at least 3 sessions per week.
Have been training continuously for at least one year.

Exclusion criteria

Participant suffering from chronic illness.
Serious or terminal illness.
Suffering from a lasting injury that prevents him/her from training in the month prior to the intervention.
Inability to understand the informed consent.
Previous experience in the consumption of beta alanine.